Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Disease-modifying treatments in multiple sclerosis].

C Confavreux1, F Bouhour, S Vukusic

  • 1Service de neurologie A Hôpital neurologique, Lyon.

La Revue Du Praticien
|December 22, 1999
PubMed
Summary

The landscape of multiple sclerosis treatments has expanded significantly since 1993, with new disease-modifying therapies offering improved options for various forms of MS. Future research aims to enhance current treatments and explore novel strategies like neuroprotection and remyelination.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study.

Muscle & nerve·2026
Same author

Target trial emulation for causal inference using observational data in neurology.

Revue neurologique·2026
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Big multiple sclerosis data network: novel modelling approaches for real-world data analysis.

Journal of neurology·2025
Same author

French guidelines for the diagnosis and management of MOG antibody-associated disease.

Revue neurologique·2025
Same author

Data linkage between the French multiple sclerosis cohort (OFSEP) and the French national health insurance database (SNDS).

Revue neurologique·2025

Area of Science:

  • Neurology
  • Immunology

Context:

  • Multiple sclerosis (MS) treatment has evolved significantly since 1993.
  • Disease-modifying agents are increasingly available for MS management.

Purpose:

  • To review the development and utility of disease-modifying agents for multiple sclerosis.
  • To highlight advancements in MS therapeutics, including interferons and glatiramer acetate.

Summary:

  • Interferon beta-1b and interferon beta-1a are effective for relapsing-remitting MS and interferon beta-1b also for secondary progressive MS.
  • Glatiramer acetate validates targeting myelin auto-reactive T-cells.
  • Global immunosuppression remains a relevant therapeutic approach.

Impact:

  • Current treatments offer better management for multiple sclerosis patients.

Related Experiment Videos

  • Future advancements may focus on optimizing efficacy, improving tolerance, and exploring neuroprotection and remyelination.